<DOC>
	<DOCNO>NCT00875615</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Infusing chemotherapy directly liver give together sorafenib may kill tumor cell . PURPOSE : This phase II trial study side effect infuse cisplatin carboplatin directly liver give together sorafenib treat patient liver cancer remove surgery .</brief_summary>
	<brief_title>Cisplatin Carboplatin Sorafenib Treating Patients With Liver Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess safety intrahepatic arterial infusion cisplatin carboplatin combination sorafenib tosylate patient unresectable hepatocellular carcinoma . Secondary - To assess time tumor progression patient treat regimen . - To assess overall progression-free survival patient treat regimen . OUTLINE : Patients receive intrahepatic arterial infusion cisplatin carboplatin 30-45 minute day 1 oral sorafenib tosylate twice daily day 8-35 . Treatment repeat every 42 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hepatocellular carcinoma ( HCC ) OR serum alpha fetoprotein ≥ 400 ng/mL radiological evidence suggestive HCC Unresectable disease ChildPugh class A select ChildPugh class B disease ( ChildPugh score ≤ 7 point ) No ChildPugh class C disease No disease outside liver macroscopic invasion major vessel portal vein No known brain metastasis Patients neurological symptom must undergo CT scan MRI brain PATIENT CHARACTERISTICS : ECOG performance status 01 WBC ≥ 3,000/mm³ ( patient schedule receive carboplatin ) ≥ 2,000/mm³ ( patient schedule receive cisplatin ) Platelet count ≥ 100,000/mm³ ( patient schedule receive carboplatin ) ≥ 60,000/mm³ ( patient schedule receive cisplatin ) Serum creatinine ≤ 1.9 mg/dL ( patient schedule receive carboplatin ) ≤ 1.5 mg/dL ( patient schedule receive cisplatin ) Serum total bilirubin ≤ 3 mg/dL AST ALT &lt; 5 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment No cardiac disease , include follow : NYHA class IIIIV congestive heart failure Unstable angina ( anginal symptom rest ) New onset angina within past 3 month Myocardial infarction within past 6 month Cardiac ventricular arrhythmia require antiarrhythmic therapy No uncontrolled hypertension , define systolic BP &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg , despite optimal medical management No thrombolic embolic event ( e.g. , cerebrovascular accident , include transient ischemic attack ) within past 6 month No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within past 4 week No hemorrhage/bleeding event ≥ CTCAE grade 3 within past 4 week No evidence history bleed diathesis coagulopathy No evidence encephalopathy No condition would impair ability swallow whole pill No history malabsorption problem No significant traumatic injury within past 4 week No serious nonhealing wound , ulcer , bone fracture No active clinically serious infection No known HIV infection No known suspect allergy sorafenib tosylate study agent PRIOR CONCURRENT THERAPY : No prior cisplatin , carboplatin , sorafenib tosylate No prior systemic chemotherapy HCC No prior systemic locoregional therapy More 4 week since prior major surgery open biopsy No concurrent St. John 's wort rifampin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
</DOC>